Novo Nordisk A/S raised its forecasts for the second time this year, citing higher expectations for its obesity and diabetes drug sales, though the magnitude of the increase failed to impress investors.
Source: [Bloomberg Markets](https://www.bloomberg.com/news/articles/2026-08-04/novo-nordisk-boosts-forecast-on-soaring-glp-1-sales)